MAGE-A1、-A9、-A11在喉鳞状细胞癌中的表达及其预后意义：一项回顾性临床研究

Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study.

作者信息

Liu Shenghui, Sang Meixiang, Xu Yuru, Gu Lina, Liu Fei, Shan Baoen

机构信息

a Research Center, the Fourth Hospital of Hebei Medical University , Shijiazhuang , Hebei , PR China ;

b Department of Otolaryngology , the Fourth Hospital of Hebei Medical University , Shijiazhuang , Hebei , PR China.

出版信息

Acta Otolaryngol. 2016;136(5):506-13. doi: 10.3109/00016489.2015.1126856. Epub 2016 Jan 14.

DOI:10.3109/00016489.2015.1126856

PMID:26766421

Abstract

CONCLUSION

The melanoma-associated antigens A1, -A9, -A11 (MAGE-A1, -A9, -A11) are relatively tumor-specific in laryngeal squamous cell carcinoma (LSCC), and could be ideal antigens for LSCC immunotherapy. In addition, MAGE-A9 probably is a poor prognostic marker for LSCC patients.

OBJECTIVE

The MAGE-A family belongs to Cancer/testis antigens (CTA). However, the expression pattern of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC is still unclear. This study aims to evaluate the expression and possible prognostic role of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC patients.

METHODS

The expression of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC specimens was investigated by immunohistochemistry, and the association of their expression and the clinical parameters and the survival of LSCC patients were analyzed by chi-square test, Kaplan-Meier survival and Cox regression analysis.

RESULTS

The expression rates of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC were 54.7%, 46.2%, and 51.9%, respectively. The expression of MAGE-A1, MAGE-A9, and MAGE-A11 in LSCC was correlated with clinical stage, lymph node metastasis, and tumor size. The overall survival of LSCC patients with positive MAGE-A1, MAGE-A9, or MAGE-A11 expression was lower than the patients without MAGE-A1, MAGE-A9, or MAGE-A11 expression. Cox's multivariable analysis showed that MAGE-A9 expression was an independently poor prognostic factor for LSCC patients.

摘要

结论

黑色素瘤相关抗原A1、-A9、-A11（MAGE-A1、-A9、-A11）在喉鳞状细胞癌（LSCC）中具有相对肿瘤特异性，可能是LSCC免疫治疗的理想抗原。此外，MAGE-A9可能是LSCC患者预后不良的标志物。

目的

MAGE-A家族属于癌胚抗原（CTA）。然而，MAGE-A1、MAGE-A9和MAGE-A11在LSCC中的表达模式仍不清楚。本研究旨在评估MAGE-A1、MAGE-A9和MAGE-A11在LSCC患者中的表达及可能的预后作用。

方法

采用免疫组织化学法检测LSCC标本中MAGE-A1、MAGE-A9和MAGE-A11的表达，并通过卡方检验、Kaplan-Meier生存分析和Cox回归分析其表达与临床参数及LSCC患者生存的相关性。

结果

LSCC中MAGE-A1、MAGE-A9和MAGE-A11的表达率分别为54.7%、46.2%和51.9%。LSCC中MAGE-A1、MAGE-A9和MAGE-A11的表达与临床分期、淋巴结转移和肿瘤大小相关。MAGE-A1、MAGE-A9或MAGE-A11表达阳性的LSCC患者的总生存期低于无MAGE-A1、MAGE-A9或MAGE-A11表达的患者。Cox多变量分析显示，MAGE-A9表达是LSCC患者独立的预后不良因素。